Abstract Library

#2837 Development and Initial Validation of a Brief Questionnaire to Assess Patient Satisfaction with Self-Injection of Lanreotide Autogel: Results During a Home Training Programme

Introduction: The long acting formulation of lanreotide autogel(LAN) can facilitate self-injection (SI) by patients or caregivers at home, avoiding visits to health centers. Training by nurses is required to ensure successful SI. Patient satisfaction(PS) is an important outcome of SI and home care programs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hernando J

Authors: Hernando J, Teulé A, Simó-Servat A, Serrano R, Venegas E,

Keywords: Lanreotide, Satisfaction, Home training,

#2802 EvAluation de Satisfaction Infirmière (Nurse Satisfaction Evaluation). Observational Study of the Preparation and Intramuscular Administration of the Previous and New Long-Acting Release Octreotide LAR Formulation (EASI)

Introduction: A new formulation of octreotide LAR (OCT LAR) with a new diluent has been developed to facilitate the preparation and administration.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Coriat R

Authors: Cadiot G, Coriat R, Raverot G, Nguyen Tan Hon T, Raingeard I,

Keywords: Octreotide LAR, NET, Acromegaly, Nurse,

#2089 Study to Evaluate the Optimal Dose of 68Ga-OPS202 as a PET Imaging Agent in Patients with GEP-NETs

Introduction: The majority of patients diagnosed with gastroenteropancreatic (GEP)-NETs present metastases expressing somatostatin receptor 2 (SSTR2). The 68Gallium-labelled SSTR2 antagonist 68Ga-OPS202 has shown improved diagnostic performance as a PET imaging agent compared with the SSTR2 agonist 68Ga-DOTA-TOC in a single-centre study.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Virgolini I, Brouwers A, Haug A, Grønbæk H, Kjær A,

Keywords: 68Ga-OPS202, GEP-NET, SSTR2, optimal dose range,

#2081 Preclinical Testing of SSA Compounds in a Model of Pancreatic Neuroendocrine Tumors to Optimize Scheduling and Drug Exposition

Introduction: Somatostatin analogues (SSA) such as Octreotide and Lanreotide have demonstrated a significant benefit in Neuroendocrine Tumors, particularly in the well/moderately differentiated types. Nevertheless, there are still several aspects of SSA treatments that remain unsolved, such as drug exposition in patients and schedule optimization.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Casanovas O

Authors: Martínez-López A, Pinto J, Lachamp L, Cabello F, Cherif-Cheikh R,

Keywords: Somatostatin Analogs, Octreotide, pNETs, dose scheduling.,

#2075 Phase 1 Pharmacokinetic and Pharmacodynamic Study of APOC, a New Controlled Release Formulation (CRF) of 15mg Octreotide Acetate in Healthy Male Volunteers

Introduction: Somatostatin analogues (SSAs) are considered the gold standard for systemic therapy of advanced neuroendocrine tumors (NETs). Octreotide is one of the SSAs most widely used in long-term therapies of NETs. There is increasing evidence that clinical benefits could be obtained with higher SSAs circulating levels but remain unreachable with current products without impacting significantly the quality of life of the patients. APOC is a new injectable controlled release technology containing Octreotide invented and developed by Ascil-Biopharm and designed to cover specifically these clinical unmet needs. It is presented as ready-to-use and can easily be manufactured at selected doses and durations in prefilled syringe.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Antonijoan Arbós R, Lachamp L, Cabello F, Molina P, Coimbra J,

Keywords: Apoc, somatostatin, analogues, controlled release, octreotide, octreotide acetate, phase 1, studies, clinical trial, study, neuroendocrine, tumor, slow, release, formulation, therapeutics, injection, drug effect, clinical, trial, im, sc,